Korro Bio Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
KRRO$15.73+5.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(amounts in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating Activities: | ||
| Net loss | $(62,382) | $(55,746) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Non-cash lease expense | 3,131 | 2,376 |
| Stock-based compensation expense | 3,105 | 1,154 |
| Depreciation expense | 2,312 | 2,645 |
| Net amortization of premiums and discounts on marketable securities | (1,159) | (80) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (893) | (14) |
| Accounts payable | (736) | 309 |
| Accrued expenses and other current liabilities | (4,765) | 1,730 |
| Operating lease liabilities | 8,578 | 1,313 |
| Other non-current assets | 230 | 137 |
| Net cash used in operating activities | (52,579) | (46,176) |
| Investing Activities: | ||
| Purchases of marketable securities | (118,132) | — |
| Proceeds from maturities of marketable securities | 14,000 | 19,000 |
| Purchases of property and equipment | (16,450) | (6,181) |
| Net cash (used in) provided by investing activities | (120,582) | 12,819 |
| Financing Activities: | ||
| Proceeds from Series B-2 convertible preferred stock, net of issuance costs | — | 45,458 |
| Proceeds from PIPE financing, net of issuance costs | 67,384 | — |
| Proceeds from exercises of stock options | 1,039 | 349 |
| Other financing activities, net | — | (2,634) |
| Net cash provided by financing activities | 68,423 | 43,173 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 2 | — |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (104,738) | 9,816 |
| Cash, cash equivalents and restricted cash, beginning of period | 173,119 | 41,477 |
| Cash, cash equivalents and restricted cash, end of period | $68,381 | $51,293 |
| Non-cash investing and financing activities: | ||
| Property and equipment capitalized under tenant improvement allowance | $7,583 | $2,138 |
| Purchases of property and equipment in accounts payable and accrued expenses | $1,401 | $167 |
| Financing costs in accounts payable and accrued expenses | $— | $965 |
| Operating lease liabilities arising from right-of-use assets | $— | $26,777 |
| Supplemental cash flow information: | ||
| Cash paid for income taxes | $47 | $27 |
| Cash paid for operating lease liabilities | $2,083 | $2,244 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.